Global trend of aetiology-based primary liver cancer incidence from 1990 to 2030: a modelling study. (8th December 2020)

• Record Type: Journal Article
• Authors: Liu, Zhenqiu; Xu, Kelin; Jiang, Yanfeng; Cai, Ning; Fan, Jiahui; Mao, Xianhua; Suo, Chen; Jin, Li; Zhang, Tiejun; Chen, Xingdong
• Is Part Of: International journal of epidemiology. Volume 50:Number 1(2021)
• Page Start: 128
• Page End: 142
• Publication Date: 2020-12-08
• Subjects: Primary liver cancer -- incidence -- prediction -- HBV -- HCV -- non-alcoholic steatohepatitis; Epidemiology -- Periodicals; 614.4
• DOI: 10.1093/ije/dyaa196
• Languages: English
• ISSNs: 0300-5771

Abstract

Abstract: Background: Predictions of primary liver cancer (PLC) incidence rates and case numbers are critical to understand and plan for PLC disease burden. Methods: Data on PLC incidence rates and case numbers from 1990 to 2017 were retrieved from the Global Burden of Disease database. The estimated average percentage change (EAPC) was calculated to quantify the trends of PLC age-standardized incidence rates (ASRs). Bayesian age-period-cohort models were constructed to project PLC incidence rates and case numbers through 2030. Results: Globally, the PLC case number doubled from 472 300 in 1990 to 953 100 in 2017. The case number will further increase to 1 571 200 in 2030, and the ASR will increase from 11.80 per 100 000 in 2018 to 14.08 per 100 000 in 2030. The most pronounced increases are observed in people afflicted by non-alcoholic steatohepatitis (NASH) and in older people. The trends of PLC incidence rates between 1990 and 2030 are heterogeneous among countries and can be summarized as five scenarios: (i) 46 countries that have and will continue to experience a persistent increase (e.g. Australia); (ii) 21 countries that experienced an initial decrease (or remained stable) but are predicted to increase (e.g. China); (iii) 7 countries that experienced an initial increase but are predicted to remain stable (e.g. USA); (iv) 29 countries that experienced an initial increase but are predicted to decrease (e.g. Egypt); and (v) 82 countries that have and will continue to experience a persistent decrease (e.g. Japan). Conclusion: PLC incidence rates and case numbers are anticipated to increase at the global level through 2030. The increases in people afflicted by NASH and among older people suggest a dearth of attention for these populations in current prevention strategies and highlight their priority in future schedules for global control of PLC.